Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance

Urokinase plasminogen activator receptor (uPAR), a member of the lymphocyte antigen 6 protein superfamily, is overexpressed in different types of cancers and plays an important role in tumorigenesis and development. In this study, we successfully targeted uPAR by CRISPR/Cas9 system in two human canc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Wang, Kun, Xing, Zi-Hao, Jiang, Qi-Wei, Yang, Yang, Huang, Jia-Rong, Yuan, Meng-Ling, Wei, Meng-Ning, Li, Yao, Wang, Sheng-Te, Liu, Kun, Shi, Zhi
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2019
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6400983/
https://ncbi.nlm.nih.gov/pubmed/30873379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00080
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares